[go: up one dir, main page]

BRPI0503418A - prognóstico para malignidade hematológica - Google Patents

prognóstico para malignidade hematológica

Info

Publication number
BRPI0503418A
BRPI0503418A BRPI0503418-3A BRPI0503418A BRPI0503418A BR PI0503418 A BRPI0503418 A BR PI0503418A BR PI0503418 A BRPI0503418 A BR PI0503418A BR PI0503418 A BRPI0503418 A BR PI0503418A
Authority
BR
Brazil
Prior art keywords
patient
methods
prognosis
hematologic malignancy
therapy
Prior art date
Application number
BRPI0503418-3A
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0503418A publication Critical patent/BRPI0503418A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROGNóSTICO PARA MALIGNIDADE HEMATOLóGICA". A presente invenção refere-se a métodos para o tratamento de pacientes de câncer, e preferencialmente malignidade hematológica, incluindo a análise de perfis de expressão de gene e/ou marcadores moleculares de um paciente para determinar a situação e/ou o prognóstico do paciente. A invenção também refere-se a métodos para analisar se um paciente não-incidente ou não-resistente é capaz de responder ao tratamento com inibidores de farnesil transferase (FTIs) e, opcionalmente, outros agentes terapêuticos. Os métodos são também úteis para monitoramento da terapia do paciente e para seleção de um curso de terapia. Os genes modulados em resposta ao tratamento com FTI são fornecidos e são usados na formulação de perfis.
BRPI0503418-3A 2004-05-06 2005-05-06 prognóstico para malignidade hematológica BRPI0503418A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56863504P 2004-05-06 2004-05-06

Publications (1)

Publication Number Publication Date
BRPI0503418A true BRPI0503418A (pt) 2006-04-11

Family

ID=35262133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0503418-3A BRPI0503418A (pt) 2004-05-06 2005-05-06 prognóstico para malignidade hematológica

Country Status (9)

Country Link
EP (1) EP1612281A3 (pt)
JP (1) JP2005333987A (pt)
KR (1) KR20060045950A (pt)
CN (1) CN1704478A (pt)
AR (1) AR048945A1 (pt)
AU (1) AU2005201935B2 (pt)
BR (1) BRPI0503418A (pt)
CA (1) CA2504403A1 (pt)
MX (1) MXPA05004971A (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598025A1 (en) * 2005-02-16 2006-08-24 Wyeth Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
JP2012513197A (ja) * 2008-12-23 2012-06-14 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 無再発生存を予測するためのメチル化バイオマーカー
RU2400750C1 (ru) * 2009-03-16 2010-09-27 Федеральное Государственное учреждение "Кировский научно-исследовательский институт гематологии и переливания крови Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "КНИИГиПК Росмедтехнологий") Способ определения факторов прогноза тяжелых геморрагических осложнений у больных острым промиелоцитарным лейкозом при диагностике
CA3007713C (en) * 2010-04-29 2020-05-26 The Regents Of The University Of California Pathway recognition algorithm using data integration on genomic models (paradigm)
RU2478206C1 (ru) * 2012-02-06 2013-03-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Способ прогнозирования рецидивов у больных острым лейкозом
CN105189783B (zh) * 2013-04-19 2020-08-07 艾皮恩蒂斯有限公司 鉴定生物样品中定量细胞组成的方法
RU2550944C2 (ru) * 2013-08-08 2015-05-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Способ прогнозирования развития терминальной стадии у больных хроническим миелолейкозом
EP3122898A1 (en) * 2014-03-26 2017-02-01 INSERM - Institut National de la Santé et de la Recherche Médicale New biomarker for outcome in aml patients
EP3873606A4 (en) * 2018-10-30 2022-10-26 MacroGenics, Inc. Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей
CN112250750B (zh) * 2020-10-21 2022-08-30 青岛肿瘤研究院 与含酪氨酸磷酸化修饰肽具有亲和力的变体sh2结构域
CN115369150A (zh) * 2022-08-05 2022-11-22 浙江丰能医药科技有限公司 一种急性白血病诊断的生物标志物分析方法及其应用
CN120366457A (zh) * 2025-04-24 2025-07-25 镇江市第一人民医院 Hoxb3基因甲基化在制备急性髓系白血病预后产品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1470247A2 (en) * 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia

Also Published As

Publication number Publication date
MXPA05004971A (es) 2005-11-23
EP1612281A2 (en) 2006-01-04
AU2005201935B2 (en) 2012-04-26
EP1612281A3 (en) 2007-02-21
AU2005201935A1 (en) 2005-11-24
CN1704478A (zh) 2005-12-07
KR20060045950A (ko) 2006-05-17
CA2504403A1 (en) 2005-11-06
AR048945A1 (es) 2006-06-14
JP2005333987A (ja) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0503418A (pt) prognóstico para malignidade hematológica
MXPA05005923A (es) Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
WO2006133420A3 (en) Treatment of patients with cancer therapy
Murray et al. Tumor angiogenesis as a prognostic factor in laryngeal cancer
Wang et al. Progress in the application of molecular biomarkers in gliomas
BRPI0513692A (pt) marcadores de urina para detecção de cáncer de bexiga
EP1410011A4 (en) DIAGNOSIS AND FORECASTING BREAST CANCER PATIENTS
WO2004000094A8 (en) Predictive markers in cancer therapy
BRPI0417213A (pt) tratamento de gliomas malìgnos com inibidores de tgf-beta
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
EP2114990A4 (en) EXPRESSION PROFILES OF GENES AND PROTEINS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
BRPI0502433A (pt) métodos para avaliação e tratamento de cáncer
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
BR0115235A (pt) Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
BRPI0515794A (pt) processos para avaliar pacientes com leucemia mielóide aguda
Lee et al. Long-term surgical outcomes in patients with hepatocellular carcinoma undergoing laparoscopic vs. open liver resection: A retrospective and propensity score-matched study
BRPI0518036A (pt) métodos e sistemas para prognóstico e tratamento de tumores sólidos
BRPI0403291A (pt) Métodos para avaliação e tratamento de câncer
BRPI0315735A8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
ATE449323T1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.